As per the terms of the agreement, Amgen has given AMG 108 development rights to MedImmune worldwide, outside Japan.
The tie up allows Amgen to get upfront payment, development-related milestone payments for multiple indications, and royalties upon sale of a commercial product.
MedImmune research and development executive vice president Bahija Jallal said that the recent data indicates the importance of the IL-1 pathway in a variety of inflammatory conditions, and AMG 108 represents a compelling opportunity to explore this antibody’s activity against various diseases for which patients need new treatment options.